Atibuclimab  (Synonyms: IC14)

Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury^[1][2].

Atibuclimab (IC14) recognizes both membrane-bound CD14 (mCD14) and soluble CD14 (sCD14)^[1].
Cluster of differentiation 14 (CD14) is a glycoprotein found on the surface of myeloid cells. CD14 functions as an accessory molecule for several toll-like receptors (TLRs), a family of pattern recognition receptors that respond to conserved patterns in pathogens and human molecules associated with inflammation and tissue injury. CD14 is a receptor for cell wall components of Gram-negative and Gram-positive bacteria that has been implicated in the initiation of the inflammatory response to sepsis^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145.5 kDa

2417175-94-9

Liquid

Colorless to light yellow

[Atibuclimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized CD14 Protein, Human (HEK293, His, HY-P7786) can bind Atibuclimab. The EC₅₀ for this effect is 22.13 ng/mL.

• [1]. Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421.  [Content Brief]

  [2]. Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605.  [Content Brief]